Targeting protein kinase a in cancer therapy: An update

EXCLI Journal

Volumn 13, Issue , 2014, Pages 843-855

  Sapio, Luigi ^a   Di Maiolo, Francesca ^a   Illiano, Michela ^a   Esposito, Antonietta ^a   Chiosi, Emilio ^a   Spina, Annamaria ^a   Naviglio, Silvio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

cAMP; cancer therapy; Designing kinase inhibitors; PKA

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE 1; CYCLIC AMP DEPENDENT PROTEIN KINASE 2; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR;

BINDING AFFINITY; BINDING SITE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL MIGRATION; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; HUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84907677474     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Antoni FA. New paradigms in cAMP signalling. Mol Cell Endocrinol 2012;353:3-9.
2. Arencibia JM, Pastor-Flores D, Bauer AF, Schulze JO, Biondi RM. AGC protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Biochim Biophys Acta 2013;1834:1302-21.
3. Awada A, Aftimos PG. Targeted therapies of solid cancers: new options, new challenges. Curr Opin Oncol 2013;25:296-304.
4. Beavo JA, Brunton LL. Cyclic nucleotide research-still expanding after half a century. Nat Rev Mol Cell Biol 2002;3:710-8.
5. Beene DL, Scott JD. A-kinase anchoring proteins take shape. Curr Opin Cell Biol 2007;19:192-8.
6. Biel M. Cyclic nucleotide-regulated cation channels. J Biol Chem 2009;284:9017-21.
7. Bossis I, Stratakis CA. PRKAR1A: normal and abnormal functions. Endocrinology 2004;145:5452-8.
8. Bossis I, Voutetakis A, Matyakhina L, Pack S, Abu-Asab M, Bourdeau I et al. A pleiomorphic GH pituitary adenoma from a Carney complex patient displays universal allelic loss at the protein kinase A regulatory subunit 1A (PRKARIA) locus. J Med Genet 2004; 41:596-600.
9. Bourdeau I, Matyakhina L, Stergiopoulos SG, Sandrini F, Boikos S, Stratakis CA. 17q22-24 chromosomal losses and alterations of protein kinase a subunit expression and activity in adrenocorticotropinindependent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2006;91:3626-32.
10. Bradbury AW, Carter DC, Miller WR, Cho-Chung YS, Clair T. Protein kinase A (PKA) regulatory subunit expression in colorectal cancer and related mucosa. Br J Cancer 1994;69:738-42.
11. Cheng HC, Kemp BE, Pearson RB, Smith AJ, Misconi L, Van Patten SM et al. A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase. J Biol Chem 1986;261:989-92.
12. Cho-Chung YS. Antisense protein kinase A RI alphainduced tumor reversion: portrait of a microarray. Biochim Biophys Acta 2004;1697:71-9.
13. Cho-Chung YS, Nesterova MV. Tumor reversion: protein kinase A isozyme switching. Ann N Y Acad Sci 2005;1058:76-86.
14. Cho-Chung YS, Nesterova M, Pepe S, Lee GR, Noguchi K, Srivastava RK et al. Antisense DNAtargeting protein kinase A-RIA subunit: a novel approach to cancer treatment. Front Biosci 1999;4:898-907.
15. Choi KY, Ahn YH, Ahn HW, Cho YJ, Hong SH. Involvement of Akt2/protein kinase B β (PKBβ) in the 8-Cl-cAMP-induced cancer cell growth inhibition. J Cell Physiol 2013;228:890-902.
16. Colzani M, Noberini R, Romanenghi M, Colella G, Pasi M, Fancelli D et al. Quantitative chemical proteomics identifies novel targets of the anti-cancer multikinase inhibitor E-3810. Mol Cell Proteomics 2014;13:1495-509.
17. de Leeuw R, Flach K, Bentin Toaldo C, Alexi X, Canisius S, Neefjes J et al. PKA phosphorylation redirects ERα to promoters of a unique gene set to induce tamoxifen resistance. Oncogene 2013;32:3543-51.
18. De Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998;396(6710):474-7.
19. Diller TC, Madhusudan, Xuong NH, Taylor SS. Molecular basis for regulatory subunit diversity in cAMP-dependent protein kinase: crystal structure of the type II beta regulatory subunit. Structure 2001; 9:73-82.
20. Edwards HV, Christian F, Baillie GS. cAMP: novel concepts in compartmentalised signalling. Semin Cell Dev Biol 2012;23:181-90.
21. Enns LC, Ladiges W. Protein kinase A signaling as an anti-aging target. Ageing Res Rev 2010;9:269-72.
22. Enns LC, Morton JF, Mangalindan RS, McKnight GS, Schwartz MW, Kaeberlein MR et al. Attenuation of age-related metabolic dysfunction in mice with a targeted disruption of the Cβ subunit of protein kinase A. J Gerontol 2009;64:1221-31.
23. Ferrari S. Protein kinases controlling the onset of mitosis. Cell Mol Life Sci 2006;63:781-95.
24. Follin-Arbelet V, Torgersen ML, Naderi EH, Misund K, Sundan A, Blomhoff HK. Death of multiple myeloma cells induced by cAMP-signaling involves downregulation of Mcl-1 via the JAK/STAT pathway. Cancer Lett 2013;335:323-31.
25. Gancedo JM. Biological roles of cAMP: variations on a theme in the different kingdoms of life. Biol Rev Camb Philos Soc 2013;88:645-68.
26. Gausdal G, Wergeland A, Skavland J, Nguyen E, Pendino F, Rouhee N et al. Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death Dis 2013;28:4:e516.
27. Gertler A, Solomon G. Leptin-activity blockers: development and potential use in experimental biology and medicine. Can J Physiol Pharmacol 2013;91:873-82.
28. Goel S, Desai K, Bulgaru A, Fields A, Goldberg G, Agrawal S et al. A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. Clin Cancer Res 2003;9:4069-76.
29. Goel S, Desai K, Macapinlac M, Wadler S, Goldberg G, Fields A et al. A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. Invest New Drugs 2006;24:125-34.
30. Gold MG, Lygren B, Dokurno P, Hoshi N, McConnachie G, Taskén K et al. Molecular basis of AKAP specificity for PKA regulatory subunits. Mol Cell 2006;24:383-95.
31. Han KC, Kim SY, Yang EG. Recent advances in designing substrate-competitive protein kinase inhibitors. Curr Pharm Des 2012;18:2875-82.
32. Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 2001;41:145-74.
33. Hensley HH, Hannoun-Levi JM, Hachem P, Mu Z, Stoyanova R, Khor LY et al. PKA knockdown enhances cell killing in response to radiation and androgen deprivation. Int J Cancer 2011;128:962-73.
34. Hochbaum D, Hong K, Barila G, Ribeiro-Neto F, Altschuler DL. Epac, in sinergy with cAMP-dependent protein kinase (PKA), is required for cAMPmediated mitogenesis. J Biol Chem 2008;283:4464-8.
35. Howe AK. Regulation of actin-based cell migration by cAMP/PKA. Biochim Biophys Acta 2004;1692: 159-74.
36. Insel PA, Zhang L, Murray F, Yokouchi H, Zambon AC. Cyclic AMP is both a pro-apoptotic and antiapoptotic second messenger. Acta Physiol (Oxf). 2012;204:277-87.
37. Jiang P, Enomoto A, Takahashi M. Cell biology of the movement of breast cancer cells: intracellular signalling and the actin cytoskeleton. Cancer Lett 2009;284:122-30.
38. Kim C, Xuong NH, Taylor SS. Crystal structure of a complex between the catalytic and regulatory (Rlα) subunits of PKA. Science 2005;307:690-6.
39. Kim C, Cheng CY, Saldanha SA, Taylor SS. PKA-I holenzyme structure reveals mechanism for cAMPdependent activation. Cell 2007;130:1032-43.
40. Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis CA. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex. Hum Mol Genet 2000;9:3037-46.
41. Knighton DR, Zheng JH, Ten Eyck LF, Ashford VA, Xuong NH, Taylor SS et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphatedependent protein kinase. Science 1991a;253:407-14.
42. Knighton DR, Zheng JH, Ten Eyck LF, Xuong NH, Taylor SS, Sowadski JM. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991b;253:414-20.
43. Kostenko S, Shiryaev A, Dumitriu G, Gerits N, Moens U. Cross-talk between protein kinase A and the MAPK-activated protein kinases RSK1 and MK5. J Recept Signal Transduct Res 2011;31:1-9.
44. Lefkimmiatis K, Zaccolo M. cAMP signaling in subcellular compartments. Pharmacol Ther 2014;S0163-7258:00069-2.
45. Loilome W, Juntana S, Namwat N, Bhudhisawasdi V, Puapairoj A, Sripa B et al. PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma. Int J Cancer 2011;129: 34-44.
46. Lucchi S, Calebiro D, de Filippis T, Grassi ES, Borghi MO, Persani L. 8-Chloro-cyclic AMP and protein kinase A I-selective cyclic AMP analogs inhibit cancer cell growth through different mechanisms. PLoS One 2011;6:e20785.
47. Madhusudan, Akamine P, Xuong NH, Taylor SS. Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase. Nat Struct Biol 2002;9:273-7.
48. Mani S, Goel S, Nesterova M, Martin RM, Grindel JM, Rothenberg ML et al. Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I. Ann N Y Acad Sci 2003;1002:252-62.
49. Mantovani G, Lania AG, Bondioni S, Peverelli E, Pedroni C, Ferrero S et al. Different expression of protein kinase A (PKA) regulatory subunits in cortisol secreting adrenocortical tumors: Relationship with cell proliferation. Exp Cell Res 2008a;314:123-30.
50. Mantovani G, Bondioni S, Lania AG, Rodolfo M, Peverelli E, Polentarutti N et al. High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells. Oncogene 2008b;27:1834-43.
51. Martin BR, Deerinck TJ, Ellisman MH, Taylor SS, Tsien RY. Isoform-specific PKA dynamics revealed by dye-triggered aggregation and DAKAP1alphamediated localization in living cells. Chem Biol 2007;14:1031-42.
52. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 2014;13:290-314.
53. Mavrakis M, Lippincott-Schwartz J, Stratakis CA, Bossis I. Depletion of type IA regulatory subunit (RIalpha) of protein kinase A (PKA) in mammalian cells and tissues activates mTOR and causes autophagic deficiency. Hum Mol Genet 2006;15:2962-71.
54. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001;2:599-609.
55. McDaid HM, Cairns MT, Atkinson RJ, McAleer S, Harkin DP, Gilmore P et al. Increased expression of the RI subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. Br J Cancer 1999;79:933-9.
56. McKenzie AJ, Campbell SL, Howe AK. Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasion. PLoS One 2011;6:e26552.
57. Merkle D, Hoffmann R. Roles of cAMP and cAMPdependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor. Cell Signal 2011;23:507-15.
58. Miller WR. Regulatory subunits of PKA and breast cancer. Ann N Y Acad Sci 2002;968:37-48.
59. Nadella KS, Kirschner LS. Disruption of protein kinase a regulation causes immortalization and dysregulation of D-type cyclins. Cancer Res 2005;65:10307-15.
60. Naviglio S, Caraglia M, Abbruzzese A, Chiosi E, Di Gesto D, Marra M et al. Protein kinase A as a biological target in cancer therapy. Expert Opin Ther Targets 2009a;13:83-92.
61. Naviglio S, Di Gesto D, Romano M, Sorrentino A, Illiano F, Sorvillo L et al. Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. Cancer Biol Ther 2009b;8:1183-90.
62. Naviglio S, Di Gesto D, Illiano F, Chiosi E, Giordano A, Illiano G et al. Leptin potentiates antiproliferative action of cAMP elevation via protein kinase A downregulation in breast cancer cells. J Cell Physiol 2010; 225:801-9.
63. Neary CL, Nesterova M, Cho YS, Cheadle C, Becker KG, Cho-Chung YS. Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion. Oncogene 2004;23:8847-56.
64. Nesterova M, Cho-Chung YS. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth. Nat Med 1995;1:528-33.
65. Nesterova M, Yokozaki H, McDuffie E, Cho-Chung YS. Overexpression of RII beta regulatory subunit of protein kinase A in human colon carcinoma cell induces growth arrest and phenotypic changes that are abolished by site-directed mutation of RII beta. Eur J Biochem 1996;235:486-94.
66. Nesterova M, Noguchi K, Park YG, Lee YN, Cho-Chung YS. Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisensedirected down-regulation of protein kinase A RIalpha protein. Clin Cancer Res 2000;6:3434-41.
67. Nesterova MV, Johnson N, Cheadle C, Bates SE, Mani S, Stratakis CA et al. Autoantibody cancer biomarker: extracellular protein kinase A. Cancer Res 2006;66:8971-4.
68. Nigg EA, Raff JW. Centrioles, centrosomes, and cilia in health and disease. Cell 2009;139:663-78.
69. Noguchi K, Murata T, Cho-Chung YS. 8-Chloradenosine 3′,5′-monophosphate (8-Cl cAMP) selectively eliminates protein kinase A type I to induce growth inhibition in c-ras-transformed fibroblasts. Eur J Cancer 1998;34:1260-7.
70. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007;100:309-27.
71. Pavan B, Biondi C, Dalpiaz A. Adenylyl cyclases as innovative therapeutic goals. Drug Discov Today 2009;14:982-91.
72. Pinna LA, Ruzzene M. How do protein kinases recognize their substrates? Biochim Biophys Acta 1996; 1314:191-225.
73. Propper DJ, Saunders MP, Salisbury AJ, Long L, O'Byrne KJ, Braybrooke JP et al. Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects. Clin Cancer Res 1999;5:1682-9.
74. Rivas M, Santisteban P. TSH-activated signaling pathways in thyroid tumorigenesis. Mol Cell Endocrinol 2003;213:31-45.
75. Robinson-White AJ, Hsiao HP, Leitner WW, Greene E, Bauer A, Krett NL et al. Protein kinase Aindependent inhibition of proliferation and induction of apoptosis in human thyroid cancer cells by 8-Cladenosine. J Clin Endocrinol Metab 2008;93:1020-9.
76. Rohlff C, Clair T, Cho-Chung YS. 8-Cl-cAMP induces truncation and down-regulation of the RIα subunit and up-regulation of the RIIβ subunit of cAMPdependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells. J Biol Chem 1993;268: 5774-82.
77. Rosen OM, Erlichman J. Reversible autophosphorylation of a cyclic 3':5'-AMP-dependent protein kinase from bovine cardiac muscle. J Biol Chem 1975;250: 7788-94.
78. Sakamoto KM, Frank DA. CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res 2009; 15:2583-7.
79. Sands WA, Palmer TM. Regulating gene transcription in response to cyclic AMP elevation. Cell Signal 2008;20:460-6.
80. Schmidt M, Dekker FJ, Maarsingh H. Exchange protein directly activated by cAMP (epac): a multidomain cAMP mediator in the regulation of diverse biological functions. Pharmacol Rev 2013;65:670-709.
81. Schwede F, Maronde E, Genieser H, Jastorff B. Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol Ther 2000;87:199-226.
82. Shaikh D, Zhou Q, Chen T, Ibe JC, Raj JU, Zhou G. cAMP-dependent protein kinase is essential for hypoxia-mediated epithelial-mesenchymal transition, migration, and invasion in lung cancer cells. Cell Signal 2012;24:2396-406.
83. Sharma K, Goehe R, Beckta JM, Valerie K, Gewirtz DA. Autophagy and radiosensitization in cancer. EXCLI Journal 2014;13:178-191.
84. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997;387:569-72.
85. Siu YT, Jin DY. CREB-a real culprit in oncogenesis. FEBS J 2007;274:3224-3.
86. Skalhegg BS, Tasken K. Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci 2000;5:678-93.
87. Spina A, Di Maiolo F, Esposito A, Sapio L, Chiosi E, Naviglio S et al. cAMP elevation down-regulates β3 integrin and focal adhesion kinase and inhibits leptininduced migration of MDA-MB-231 breast cancer cells. Biores Open Access 2012;1:324-32.
88. Spina A, Di Maiolo F, Esposito A, D'Auria R, Di Gesto D, Naviglio S et al. Integrating leptin and cAMP signalling pathways in triple-negative breast cancer cells. Front Biosci 2013;18:133-44.
89. Steinberg SF, Brunton LL. Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. Annu Rev Pharmacol Toxicol 2001;41:751-73.
90. Stork PJ, Schmitt JM. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 2002;12:258-66.
91. Su Y, Dostmann WR, Herberg FW, Durick K, Xuong NH, Ten Eyck L et al. Regulatory subunit of protein kinase A: structure of deletion mutant with cAMP binding domains. Science 1995;269:807-13.
92. Tai Z, Lin Y, He Y, Huang J, Guo J, Yang L et al. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells. Cell Signal 2014;26:619-28.
93. Taskén K, Skalhegg BS, Taskén KA, Solberg R, Knutsen HK, Levy FO et al. Structure, function, and regulation of human cAMP-dependent protein kinases. Adv Second Messenger Phosphoprotein Res 1997;31:191-204.
94. Taylor SS, Zhang P, Steichen JM, Keshwani MM, Kornev AP. PKA: lessons learned after twenty years. Biochim Biophys Acta 2013;1834:1271-8.
95. Tortora G, Ciardiello F. Protein kinase A as target for novel integrated strategies of cancer therapy. Ann N Y Acad Sci 2002;968:139-47.
96. Tortora G, Ciardiello F. Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy. Ann N Y Acad Sci 2003;1002:236-43.
97. Tröger J, Moutty MC, Skroblin P, Klussmann E. Akinase anchoring proteins as potential drug targets. Br J Pharmacol 2012;166:420-33.
98. Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. Antitumor activity and pharmacokinetics of a mixedbackbone oligonucleotide targeted to the RIalpha subunit of protein kinase A following oral administration. Proc Natl Acad Sci USA 1999;96:13989-94.
99. Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER et al. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol 2002;21:73-80.
100. Wang H, Li M, Lin W, Wang W, Zhang Z, Rayburn ER et al. Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients. Cancer Epidemiol Biomarkers Prev 2007;16:789-95.
101. Waschek JA, Dicicco-Bloom E, Nicot A, Lelievre V. Hedgehog signaling: New targets for GPCRs coupled to cAMP and protein kinase A. Ann NY Acad Sci 2006;1070:120-8.
102. Willoughby D, Cooper DM. Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev 2007;87:965-1010.
103. Wu J, Brown SH, von Daake S, Taylor SS. PKA type IIα holoenzyme reveals a combinatorial strategy for isoform diversity. Science 2007;318:274-9.
104. Wu KJ, Mattioli M, Morse HC, Dalla-Favera R. c-MYC activates protein kinase A (PKA) by direct transcriptional activation of the PKA catalytic subunit beta (PKA-Cbeta) gene. Oncogene 2002;21:7872-82.
105. Yu S, Huang H, Iliuk A, Wang WH, Jayasundera KB, Tao WA et al. Syk inhibits the activity of protein kinase A by phosphorylating tyrosine 330 of the catalytic subunit. J Biol Chem 2013;288:10870-81.